Navigation Links
John Garibotto Joins Cellnovo's Board of Directors
Date:6/20/2013

SWANSEA, England, June 21, 2013 /PRNewswire/ --

Cellnovo, the leading innovator in mobile diabetes management technology, announced today the appointment of John Garibotto as non-executive director.

Mr. Garibotto is a 20 year veteran of the medical device industry and has been instrumental in the development, formation, and financing of highly successful medical device companies including Insulet Corporation (IPO May 2007, Nasdaq: PODD) and TransVascular, Inc. (acquired by Medtronic in Sept '04).  He is presently the founder and Chief Technology Officer of Securus Medical Group, Inc.  Mr. Garibotto has earned a B.Sc. in Industrial Technology from the University of Massachusetts at Lowell and a Masters in Business Administration from Northeastern University.

"It is a real pleasure to welcome John as director," said Eric Beard, Cellnovo's Executive Chairman.  "John has vast experience in complex medical device development.  His expertise and guidance will be invaluable as we prepare to submit our mobile-diabetes management system for US approval."

"I'm delighted to join the board of this outstanding company," said John Garibotto.  "Cellnovo has developed a game-changing approach to the treatment and follow up of patients with type 1 diabetes.  I am very impressed by the mobile, real-time technology that Cellnovo have used for their system, which will undoubtedly address the many unmet needs of both patient and care teams."

About Cellnovo

A UK-based medical device company, Cellnovo develops an innovative mobile diabetes management system. Comprised of a mobile connected patch pump, mobile touchscreen handset/controller, blood glucose meter and applications, the Cellnovo system provides intuitive operation, wireless Internet connectivity and real-time tracking, all industry firsts. For further information, please visit http://www.cellnovo.com.


'/>"/>
SOURCE Cellnovo
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
2. John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations
3. Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board
4. StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500
5. Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
6. Dalia Dergham Joins Grace Century FZ LLC International Project Team
7. SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions
8. Elissa Guerra Joins Pursuit as VP of Client Solutions
9. Graphene joins the race to redefine the ampere
10. Provia Laboratories, LLC Joins Stoneham Chamber of Commerce in Massachusetts
11. Provonix Joins the Medrio Partner Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... 23, 2017  Imanis Life Sciences announced today ... oncolytic vaccinia viruses for virotherapy research. These viruses ... Genelux,s proprietary, vaccinia virus-based technology platform for research ... into a partnership with Genelux to offer researchers, ... for use in research," said Dr. Kah ...
(Date:2/23/2017)... ... 2017 , ... Today, researchers can fast-track sample collection and ... other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With the ... between insulin and other relevant biomarkers can be extensively studied through a non-invasive ...
(Date:2/23/2017)... and SAN FRANCISCO , Feb. ... regenerative medicine company, and Beyond Type 1, a not-for-profit ... 1 diabetes, today announced a grant from Beyond Type ... cure for type 1 and other insulin-requiring diabetes.  ... been developing innovative stem cell-derived cell replacement therapies with ...
Breaking Biology Technology:
(Date:2/7/2017)... Feb. 7, 2017   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... its innovative, highly flexible and award winning eClinical solution, ... iMedNet is a proven Software-as-a-Service (SaaS) clinical ... Capture (EDC), but also delivers an entire suite of ...
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
(Date:2/2/2017)... TOKYO , Feb. 1, 2017  Central ... innovative and meaningful advances worldwide, The Japan Prize ... Japan Prize, who have pushed the envelope in ... Information and Communication. Three scientists are being recognized ... outstanding achievements that not only contribute to the ...
Breaking Biology News(10 mins):